Schuth Alexander O.'s Form 4 filing
Denali Therapeutics Inc. (DNLI) · filed Sep 9, 2021
- Accession no.
- 0001714899-21-000090
- Filed
- Sep 9, 2021
- Trade date
- Sep 7, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $555.5K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schuth Alexander O.CIK 0001724311 | Officer (COO and Secretary) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 7, 2021 | Common Stock | SSaleDisposed | −2,209 | $54.70F2 | −$120,832.3 | 481,829 | Indirect | |
| Sep 7, 2021 | Common Stock | SSaleDisposed | −5,350 | $55.67F4 | −$297,834.5 | 476,479 | Indirect | |
| Sep 7, 2021 | Common Stock | SSaleDisposed | −2,441 | $56.05F5 | −$136,818.05 | 474,038 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $54.01 to $55.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $55.01 to $55.98 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F5
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $56.00 to $56.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.